CoLucid Pharmaceuticals Company Profile (NASDAQ:CLCD)

Analyst Ratings

Consensus Ratings for CoLucid Pharmaceuticals (NASDAQ:CLCD) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.00 (134.04% upside)

Analysts' Ratings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Show:
DateFirmActionRatingPrice TargetActions
11/10/2015William BlairInitiated CoverageBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015Ladenburg ThalmannInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015Stifel NicolausInitiated CoverageBuy$15.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015Piper Jaffray Cos.Initiated CoverageOverweight$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/11/2016Q1($0.73)($0.85)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q3($0.63)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015($0.35)($1.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CoLucid Pharmaceuticals (NASDAQ:CLCD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.71)($0.71)($0.71)
Q3 20161($0.71)($0.71)($0.71)
Q4 20161($0.71)($0.71)($0.71)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/20/2016Raymond SkwierczynskiInsiderSell508$8.97$4,556.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2016Raymond SkwierczynskiInsiderSell508$9.10$4,622.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2016Raymond SkwierczynskiInsiderSell516$7.01$3,617.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2016Raymond SkwierczynskiInsiderSell1,008$6.80$6,854.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Thomas P MathersCEOSell1,502$7.25$10,889.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2016Vi Associates L.P. DpMajor ShareholderSell235$6.96$1,635.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015Thomas P MathersCEOBuy7,500$7.10$53,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015A/S NovoMajor ShareholderBuy1,300,000$10.00$13,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Arthur M PappasDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for CoLucid Pharmaceuticals (NASDAQ:CLCD)
DateHeadline
06/22/16 03:01 PMCoLucid Pharmaceuticals Hosting Key Opinion Leader Meeting in New York City - [GlobeNewswire] - CAMBRIDGE, Mass., June 22, 2016-- CoLucid Pharmaceuticals, Inc., a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, ...
06/08/16 05:04 PMCoLucid Pharmaceuticals, Inc. :CLCD-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/07/16 07:48 AMCoLucid Pharmaceuticals Announces Last Patient Randomized in SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine - [at noodls] - CAMBRIDGE, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (http://finance.yahoo.com/q?s=clcd'; data-rapid_p='8'>CLCD), a Phase 3 clinical-stage biopharmaceutical company that ...
06/02/16 07:58 AMCoLucid Pharmaceuticals to Participate at the Jefferies 2016 Healthcare Conference - [GlobeNewswire] - CAMBRIDGE, Mass., June 02, 2016-- CoLucid Pharmaceuticals, Inc., a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, ...
06/01/16 07:15 AMCoLucid Pharmaceuticals (CLCD) in Focus: Stock Rises 11.1% -
05/27/16 12:20 PMStock Rating Review for CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) - Wall Street Hints and News - Stock Rating Review for CoLucid Pharmaceuticals Inc (NASDAQ:CLCD)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD). Covering ...and more »
05/26/16 11:25 AMTarget Check and Stock Performance Recap CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) - Wall Street Hints and News - Target Check and Stock Performance Recap CoLucid Pharmaceuticals Inc (NASDAQ:CLCD)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, CoLucid Pharmaceuticals Inc ...and more »
05/19/16 11:47 AMCoLucid Pharmaceuticals Announces Initiation of Second Phase 3 Pivotal Trial of Lasmiditan in Migraine - [GlobeNewswire] - First Patient Randomized in SPARTAN Study Trial Being Conducted Under Special Protocol Assessment Agreement with FDA. CAMBRIDGE, Mass., May 19, 2016-- CoLucid Pharmaceuticals, Inc., a Phase 3 clinical-stage ...
05/11/16 04:42 PMCoLucid Pharmaceuticals posts 1Q loss -
05/11/16 04:17 PMCoLucid Pharmaceuticals Announces 2016 First Quarter Results and Corporate Highlights - [at noodls] - CoLucid Pharmaceuticals Announces 2016 First Quarter Results and Corporate Highlights
04/03/16 01:56 PMColucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Sellers Increased By 3.68% Their Shorts - RiversideGazette.com - Colucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Sellers Increased By 3.68% Their ShortsRiversideGazette.comThe short interest to Colucid Pharmaceuticals Incorporated's float is 3.8%. The stock increased 10.16% or $0.63 on April 1, hitting $6.83. About 19,785 shares traded hands or 95.43% up from the average. CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) has ...and more »
03/29/16 12:04 PMCOLUCID PHARMACEUTICALS, INC. Financials -
03/24/16 05:07 AMCOLUCID PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report -
03/20/16 01:43 PMCoLucid Pharmaceuticals, Inc. (CLCD): Analyst Targets For The Coming Week - Share Trading News - CoLucid Pharmaceuticals, Inc. (CLCD): Analyst Targets For The Coming WeekShare Trading NewsRecently some investment brokers have made changes to their outstanding price targets on shares of CoLucid Pharmaceuticals, Inc. (CLCD). According to data from Reuters, 3 analysts have a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, ...and more »
03/15/16 01:46 PMChanges To Broker Targets On CoLucid Pharmaceuticals, Inc. (CLCD) - Share Trading News - Changes To Broker Targets On CoLucid Pharmaceuticals, Inc. (CLCD)Share Trading NewsThey now have a USD 21 price target on the stock. The share price of CoLucid Pharmaceuticals, Inc. (CLCD) was down -2.14% during the last trading session, with a day high of 6.69. 6440 shares were traded on CoLucid Pharmaceuticals, Inc.'s last session.Colucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Short Interest Decreased By 5.09%SmallCapWired.comCoLucid Pharmaceuticals Announces Election of Alison Lawton to Board of DirectorsEconoTimesall 4 news articles »
03/15/16 07:00 AMCoLucid Pharmaceuticals Announces Election of Alison Lawton to Board of Directors - [GlobeNewswire] - CAMBRIDGE, Mass., March 15, 2016-- CoLucid Pharmaceuticals, Inc., a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of ...
03/11/16 01:22 PMCoLucid Pharmaceuticals, Inc. (CLCD) Broker Updates - Risers & Fallers - CoLucid Pharmaceuticals, Inc. (CLCD) Broker UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of CoLucid Pharmaceuticals, Inc. (CLCD). According to the latest broker reports outstanding on Friday 11th of March, 3 analysts have a rating of “strong buy”, 1 analysts ...
03/10/16 01:33 PMAverage Rating Update on CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) - Business Standard Tribune - Average Rating Update on CoLucid Pharmaceuticals Inc (NASDAQ:CLCD)Business Standard TribuneWall Street analysts have an average broker recommendation of 1 on CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) shares. The rating is determined by taking the average of all analyst recommendations taken into consideration by Zacks Research.and more »
03/09/16 01:38 PMCoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Analyst Rating & Update - WallStreet.org - CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Analyst Rating & UpdateWallStreet.orgBoth the crowd and Wall Street have recently chimed on with their opinions of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) shares. Beta Systems research tracks crows sourced sentiment and offers consensus ratings on stocks. These ratings come from ...and more »
03/09/16 01:38 PMCoLucid Pharmaceuticals, Inc. (CLCD) Updated Price Targets - Share Trading News - CoLucid Pharmaceuticals, Inc. (CLCD) Updated Price TargetsShare Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of CoLucid Pharmaceuticals, Inc. (CLCD). The most recent broker reports which have been released note that 3 analysts ...
03/08/16 01:33 PMUpdated Price Targets On CoLucid Pharmaceuticals, Inc. (CLCD) - Risers & Fallers - Updated Price Targets On CoLucid Pharmaceuticals, Inc. (CLCD)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of CoLucid Pharmaceuticals, Inc. (CLCD). The latest broker reports which are currently outstanding on Tuesday 8th of March state 3 analysts have a rating of “strong buy”, ...and more »
03/03/16 01:21 PMColucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Short Interest Increased By 7.44% - RiversideGazette.com - Colucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Short Interest Increased By 7.44%RiversideGazette.comThe short interest to Colucid Pharmaceuticals Incorporated's float is 3.86%. The stock increased 0.57% or $0.03 on March 2, hitting $6.14. About 8,852 shares traded hands. CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) has declined 30.41% since July 28, ...CoLucid Pharmaceuticals to Present Corporate Overview at the Cowen & Company 36th Annual Health Care ConferenceGlobeNewswire (press release)CoLucid Pharmaceuticals Announces 2015 Fourth Quarter and Year-End Results and Corporate HighlightsEconoTimesall 11 news articles »
03/03/16 07:00 AMCoLucid Pharmaceuticals to Present Corporate Overview at the Cowen & Company 36th Annual Health Care Conference - [GlobeNewswire] - CAMBRIDGE, Mass., March 03, 2016-- CoLucid Pharmaceuticals, Inc. today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at the Cowen& Company 36 th Annual Health ...
03/02/16 04:27 PMCoLucid Pharmaceuticals posts 4Q loss -
03/02/16 03:23 PMCoLucid Pharmaceuticals Announces 2015 Fourth Quarter and Year-End Results and Corporate Highlights - [GlobeNewswire] - CAMBRIDGE, Mass., March 02, 2016-- CoLucid Pharmaceuticals, Inc. today reported financial and operating results for the fourth quarter and year ended December 31, 2015.. During the fourth quarter, CoLucid ...
03/02/16 12:59 PMStock Moving Upward: CoLucid Pharmaceuticals, Inc.( NASDAQ:CLCD ) - Stock Caller - Stock Moving Upward: CoLucid Pharmaceuticals, Inc.( NASDAQ:CLCD )Stock CallerShares of CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) have shown positive gains in today's trading session. At the time of writing, the stock had hit $5.89. This represents a change from the opening price of -0.03%. The year-to-date performance of the ...and more »
03/02/16 12:59 PMStock Rating & Analysis on CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) - WallStreet.org - Stock Rating & Analysis on CoLucid Pharmaceuticals Inc (NASDAQ:CLCD)WallStreet.orgCoLucid Pharmaceuticals Inc (NASDAQ:CLCD) company shares are recently being watched closely by Wall Street professionals and certain individuals that give personal stock ratings (crowd). Although company fundamentals are important when predicting ...and more »
03/01/16 01:17 PMCoLucid Pharmaceuticals, Inc. (CLCD) New Analyst Ratings - Share Trading News - CoLucid Pharmaceuticals, Inc. (CLCD) New Analyst RatingsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of CoLucid Pharmaceuticals, Inc. (CLCD). The latest reports which are currently in issue on Tuesday 1st of March state 3 analysts have a rating of “strong buy”, 1 analysts ...Price Target Update On CoLucid Pharmaceuticals, Inc. (CLCD)Risers & FallersCoLucid Pharmaceuticals Announces Special Protocol Agreement for SPARTANGlobeNewswire (press release)all 4 news articles »
03/01/16 07:02 AM8:02 am CoLucid Pharmaceuticals receives a Special Protocol Agreement for second phase 3 trial from US FDA -
03/01/16 07:00 AMCoLucid Pharmaceuticals Announces Special Protocol Agreement for SPARTAN - [GlobeNewswire] - CAMBRIDGE, Mass., March 01, 2016-- CoLucid Pharmaceuticals, Inc., a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of ...
02/29/16 01:18 PMPrice Target Update On CoLucid Pharmaceuticals, Inc. (CLCD) - Risers & Fallers - Price Target Update On CoLucid Pharmaceuticals, Inc. (CLCD)Risers & FallersA number of investment brokers have recently updated their price targets on shares of CoLucid Pharmaceuticals, Inc. (CLCD). According to the latest broker reports 3 analysts have a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, 0 analysts ...and more »
02/29/16 01:18 PMWhat to Expect from CoLucid Pharmaceuticals Inc (CLCD) EPS? - OctaFinance.com - What to Expect from CoLucid Pharmaceuticals Inc (CLCD) EPS?OctaFinance.comAnalysts await CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) to reports earnings on March, 1. After $-0.59 actual earnings per share reported by CoLucid Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 11.86 % negative EPS growth.Colucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Shorted Shares Increased By 7.44%Stock Callerall 2 news articles »
02/24/16 12:52 PMCoLucid Pharma Reports Confirmatory Support for Non-Vasoconstrictive Mechanism of ACtion for Lasmiditan - Benzinga - CoLucid Pharma Reports Confirmatory Support for Non-Vasoconstrictive Mechanism of ACtion for LasmiditanBenzingaCoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, announced today the completion of a preclinical ...CoLucid Pharmaceuticals Inc's Bullish Inverse H&S Chart Pattern Points to Lower Stock RisksBusiness Standard TribuneCoLucid Pharmaceuticals Reports Confirmatory Support for Non-vasoconstrictive Mechanism of Action for LasmiditanInvesting News Network (press release) (registration) (blog)CoLucid Pharmaceuticals Announces Confirmatory Support for Non-vasoconstrictive Mechanism of Action for LasmiditanGlobeNewswire (press release)all 7 news articles »
02/23/16 12:24 PMCoLucid Pharma Reports Confirmatory Support for Non-Vasoconstrictive Mechanism of ACtion for Lasmiditan - CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, announced today the completion of a preclinical in ...
02/23/16 12:24 PMCoLucid Pharmaceuticals : Reports Confirmatory Support for Non-vasoconstrictive Mechanism of Action for Lasmiditan - CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) announced the completion of a preclinical in vivo study examining the effect of lasmiditan on coronary and carotid artery diameters. This study confirms the lack of effect of lasmiditan on coronary artery and ...
02/23/16 07:12 AMCoLucid Pharmaceuticals Announces Confirmatory Support for Non-vasoconstrictive Mechanism of Action for Lasmiditan - [GlobeNewswire] - CAMBRIDGE, Mass., Feb. 23, 2016-- CoLucid Pharmaceuticals, Inc., a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of ...
02/20/16 12:38 PMColucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Short Interest Decreased By 1.41% - Franklin Independent - Colucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Short Interest Decreased By 1.41%Franklin IndependentThe short interest to Colucid Pharmaceuticals Incorporated's float is 3.6%. The stock decreased 0.37% or $0.02 on February 19, hitting $5.38. About 10,848 shares traded hands. CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) has declined 38.51% since July ...
02/13/16 12:34 PMColucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Short Interest Decreased By 1.41% - fdanewsalert.com - Colucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Short Interest Decreased By 1.41%fdanewsalert.comThe short interest to Colucid Pharmaceuticals Incorporated's float is 3.6%. The stock decreased 0.18% or $0.01 on February 12, hitting $5.44. About 7,588 shares traded hands. CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) has declined 36.82% since July ...
02/12/16 07:45 AMCoLucid Pharmaceuticals (CLCD) in Focus: Stock Up 9.9% -
02/11/16 12:38 PMRecent Broker Updates On CoLucid Pharmaceuticals, Inc. (CLCD) - Risers & Fallers - Recent Broker Updates On CoLucid Pharmaceuticals, Inc. (CLCD)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of CoLucid Pharmaceuticals, Inc. (CLCD). The latest broker reports which are currently outstanding on Thursday 11th of February state 3 analysts have a rating of “strong buy ...
02/09/16 12:19 PMColucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Shorted Shares Increased 6.9% After Market Selling - fdanewsalert.com - Colucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Shorted Shares Increased 6.9% After Market Sellingfdanewsalert.comThe short interest to Colucid Pharmaceuticals Incorporated's float is 3.65%. The stock is down 4.35% or $0.25 after the news, hitting $5.5 per share. About 2,324 shares traded hands. CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) has declined 33.22% since ...
02/09/16 12:19 PMAnalysts Forecast Higher CoLucid Pharmaceuticals Inc (CLCD) Earnings Per Share - WallStreet.org - Analysts Forecast Higher CoLucid Pharmaceuticals Inc (CLCD) Earnings Per ShareWallStreet.orgWall Street await CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) to release earnings on February, 9. After releasing $-0.59 EPS for the previous quarter, CoLucid Pharmaceuticals Inc's analysts now forecasts 11.86% negative EPS growth. The stock ...
02/05/16 12:50 PMCoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) to Ring The Nasdaq Stock Market Closing Bell - Nasdaq - CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) to Ring The Nasdaq Stock Market Closing BellNasdaqCoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, will visit the Nasdaq MarketSite in Times Square.and more »
02/05/16 09:00 AMCoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) to Ring The Nasdaq Stock Market Closing Bell - [GlobeNewswire] - What: CoLucid Pharmaceuticals, Inc., a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, will visit ...
02/02/16 12:03 PMCoLucid Pharmaceuticals, Inc. (CLCD) Recent Analyst Updates - Risers & Fallers - CoLucid Pharmaceuticals, Inc. (CLCD) Recent Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of CoLucid Pharmaceuticals, Inc. (CLCD). According to the latest broker reports outstanding on Tuesday 2nd February, 3 analysts have a rating of “strong buy”, 1 analysts ...CoLucid Pharmaceuticals to Present Corporate Overview at the BIO CEO & Investor Confe...CNNMoneyall 4 news articles »
02/02/16 07:00 AMCoLucid Pharmaceuticals to Present Corporate Overview at the BIO CEO & Investor Conference - [GlobeNewswire] - CAMBRIDGE, Mass., Feb. 02, 2016-- CoLucid Pharmaceuticals, Inc. today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at the BIO CEO& Investor Conference, being ...
11/10/15 02:36 PMCoLucid Pharmaceuticals Announces Third Quarter 2015 Results and Corporate Highlights - [at noodls] - CoLucid Pharmaceuticals Announces Third Quarter 2015 Results and Corporate Highlights
11/10/15 07:31 AMCOLUCID PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
10/30/15 11:50 AMTeladoc (TDOC): What's in Store this Earnings Season? -
10/27/15 03:13 PMCOLUCID PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and -

Social

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals logoCoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. The Company's product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine headaches in adults. The Company is developing intravenous lasmiditan for the acute treatment of unspecified non-traumatic primary headache in adults in emergency room and other urgent care settings, and other unmet medical needs. Lasmiditan is designed to treat migraine using a mechanism by acting as an agonist at the fifth human serotonin receptor. Lasmiditan is designed to penetrate the central nervous system and to block the pathway that contributes to headache.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLCD
  • CUSIP:
Key Metrics:
  • Previous Close: $9.40
  • 50 Day Moving Average: $7.98
  • 200 Day Moving Average: $6.74
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $143.58M
  • Beta: 1.89
  • Current Year EPS Consensus Estimate: $-3.28 EPS
  • Next Year EPS Consensus Estimate: $-2.42 EPS
Additional Links:
CoLucid Pharmaceuticals (NASDAQ:CLCD) Chart for Wednesday, July, 27, 2016